Tazocin Indications/Uses

Treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected:
Lower respiratory tract infections; urinary tract infections (complicated and uncomplicated); intra-abdominal infections; skin and skin structure infections; bacterial septicaemia.
Polymicrobic Infections: Tazocin is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, lower respiratory tract).
Tazocin, in combination with an aminoglycoside, is indicated for bacterial infections in neutropenic adults or children.
In hospitalized children 2-12 years, piperacillin/tazobactam is indicated for the treatment of intra-abdominal infections including appendicitis complicated by rupture or abscess, peritonitis and biliary infections. It has not been evaluated in this indication for pediatric patients <2 years.
While Tazocin is indicated only for the conditions previously mentioned, infections caused by piperacillin-susceptible organisms are also amenable to Tazocin treatment due to its piperacillin content. Therefore, treatment of mixed infections caused by piperacillin-susceptible organisms and β-lactamase-producing organisms susceptible to Tazocin should not require the addition of another antibiotic.
Tazocin is particularly useful in the treatment of mixed infections and in presumptive therapy prior to the availability of the results of sensitivity tests because of its broad spectrum of activity.
Tazocin acts synergistically with aminoglycosides against certain strains of Pseudomonas aeruginosa. Combined therapy has been successful, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted if necessary.